Stanford researchers have developed a targeted therapy for Alzheimer's disease that focuses on inhibiting the spread of tau protein, a key factor in disease progression.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.